Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 125

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 125
---
 J – Segment Reporting for information on our reportable segments.Three Months Ended March 31,Geographic Regions20252024U.S.$2,960 $2,258 Europe, Middle East and Africa846 803 Asia-Pacific701 647 Latin America and Canada155 149 Total Net Sales$4,663 $3,856 Emerging Markets(1)$690 $648 

30

(1) Our Emerging Markets countries include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada.Deferred RevenueContract liabilities are classified within Other current liabilities and Other long-term liabilities within our accompanying unaudited consolidated balance sheets. Our deferred revenue balance was $641 million as of March 31, 2025 and $635 million as of December 31, 2024. Our contract liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiology business, for which revenue is recognized over the average service period based on device and patient longevity. Our contract liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor system, also within our Cardiology business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $68 million in the first quarter of 2025 that was included in the above contract liability balance as of December 31, 2024. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Variable Consideration

For additional information on variable consideration, refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K. 

NOTE L – CHANGES IN OTHER COMPREHENSIVE INCOMEThe following tables provide the reclassifications out of Other comprehensive income (loss), net of tax attributable to Boston Scientific common stockholders: (in millions)Foreign Currency Translation AdjustmentNet Change in Derivative Financial InstrumentsNet Change in Defined Benefit Pensions and Other ItemsTotalBalance as of December 31, 2024$136 $155 $(16)$275 Other comprehensive income (loss) before reclassifications(212)(55)(0)(267)(Income) loss amounts reclassified from accumulated other comprehensive income(4)(